Показано 0 из 0
Дата |
---|
23.02.2022 |
22.02.2022 |
18.02.2022 |
16.02.2022 |
15.02.2022 |
14.02.2022 |
11.02.2022 |
10.02.2022 |
09.02.2022 |
08.02.2022 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1 573.00
|
1 576.00
|
0
|
0
|
0
|
0
|
|
|
|
|
1 539.00
|
1 543.00
|
1 548.00
|
1 548.00
|
1 548.00
|
1 548.00
|
|
1 548.00
|
3 096.00
|
2.00
|
1 513.00
|
1 516.00
|
1 490.00
|
1 490.00
|
1 490.00
|
1 490.00
|
|
1 490.00
|
4 470.00
|
1.00
|
1 446.00
|
1 449.00
|
0
|
0
|
0
|
0
|
|
|
|
|
1 448.00
|
1 451.00
|
1 456.00
|
1 456.00
|
1 456.00
|
1 456.00
|
|
1 456.00
|
2 912.00
|
1.00
|
1 430.00
|
1 433.00
|
0
|
0
|
0
|
0
|
|
|
|
|
1 452.00
|
1 455.00
|
0
|
0
|
0
|
0
|
|
|
|
|
1 408.00
|
1 412.00
|
0
|
0
|
0
|
0
|
|
|
|
|
1 444.00
|
1 447.00
|
1 426.00
|
1 425.00
|
1 426.00
|
1 425.00
|
|
1 426.00
|
85 559.00
|
2.00
|
1 422.00
|
1 425.00
|
0
|
0
|
0
|
0
|
|
|
|
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.